EAOCRC Summit Framing the Conversation: Strategic Challenges in Current Medical Care that Contribute to Young Adult Colorectal Cancer (CRC) Incidence and Mortality. Session I - The Dimensions of the EAOCRC Problem.
5th Annual Early Age Onset Colorectal Cancer Summit - Session II: Family History Ascertainment in the US - What Steps are Needed to Improve the Well Documented Less Than Optimal Status of this Situation?
As part of the 4th Annual Early Age Onset CRC Summit theNational Colorectal Cancer Roundtable (NCCRT) Family History and Early Onset Task Group hosted a Special Symposium focused on the importance of Family Health History for colorectal cancer, including advanced adenomas, and its importance in preventing colorectal cancer. The Symposium included presentations on the current challenges and opportunities surrounding ascertainment and documentation of actionable family health history information in primary care.
5th Annual Early Age Onset Colorectal Cancer Summit - Session III: Earliest Possible Diagnosis and Treatment Through Timely Recognition of Symptoms and Signs of Young Adult CRC
Don’t miss our upcoming webinars: Subscribe today!
In this webinar:
Join CCSN and Marjut Huotari, VP-Healthcare Insights at Leger, as we present the results of the COVID-19 and Cancer Care Disruption in Canada Survey and hear from members of the cancer community about how the pandemic has directly impacted them.
View the video:
https://youtu.be/6ub1ot806-A
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don’t miss our upcoming webinars: Subscribe today!
In this webinar:
Our presenter, Filomena Servidio, will be reviewing the results of CCSN’s National Prostate Cancer Survey based on the recently released Prostate Cancer Survey Report. Join us as we learn more about the prostate cancer journey, and the need to better inform and support prostate cancer patients and their caregivers in Canada.
View the video:
https://youtu.be/RHwIsZx6x4A
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
In this webinar, Dr. Durand will review the changing landscape of HPV-related diseases and cancers. She will discuss methods of HPV prevention for current cancer patients and cancer survivors. Attendees will learn about the evidence for HPV vaccination in adults. Practical tips will be provided on how to access HPV vaccination.
View the YouTube video: https://youtu.be/wFgpmqOpzC4
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
5th Annual Early Age Onset Colorectal Cancer Summit - Session II: Family History Ascertainment in the US - What Steps are Needed to Improve the Well Documented Less Than Optimal Status of this Situation?
As part of the 4th Annual Early Age Onset CRC Summit theNational Colorectal Cancer Roundtable (NCCRT) Family History and Early Onset Task Group hosted a Special Symposium focused on the importance of Family Health History for colorectal cancer, including advanced adenomas, and its importance in preventing colorectal cancer. The Symposium included presentations on the current challenges and opportunities surrounding ascertainment and documentation of actionable family health history information in primary care.
5th Annual Early Age Onset Colorectal Cancer Summit - Session III: Earliest Possible Diagnosis and Treatment Through Timely Recognition of Symptoms and Signs of Young Adult CRC
Don’t miss our upcoming webinars: Subscribe today!
In this webinar:
Join CCSN and Marjut Huotari, VP-Healthcare Insights at Leger, as we present the results of the COVID-19 and Cancer Care Disruption in Canada Survey and hear from members of the cancer community about how the pandemic has directly impacted them.
View the video:
https://youtu.be/6ub1ot806-A
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don’t miss our upcoming webinars: Subscribe today!
In this webinar:
Our presenter, Filomena Servidio, will be reviewing the results of CCSN’s National Prostate Cancer Survey based on the recently released Prostate Cancer Survey Report. Join us as we learn more about the prostate cancer journey, and the need to better inform and support prostate cancer patients and their caregivers in Canada.
View the video:
https://youtu.be/RHwIsZx6x4A
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
In this webinar, Dr. Durand will review the changing landscape of HPV-related diseases and cancers. She will discuss methods of HPV prevention for current cancer patients and cancer survivors. Attendees will learn about the evidence for HPV vaccination in adults. Practical tips will be provided on how to access HPV vaccination.
View the YouTube video: https://youtu.be/wFgpmqOpzC4
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars: Subscribe today!
In this webinar:
Dr. Paula Gordon will share information on when individuals should start screening for breast cancer, and how often to screen - in order for cancer to be found as early as possible, and to allow the least aggressive options for treatment. Dr. Gordon will also discuss how to screen for recurrence in women who’ve had cancer, explain why these methods are not always offered, and suggest what you can do to improve access to optimal screening.
View the video: https://youtu.be/7uFksz6_4Zk
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
Presented by: Dr. Paul C Rogers, MBChB, FRCPC, FRCP(Lond), MBA
In this webinar, Dr. Rogers will discuss:
1) Nutrition from a cancer control perspective
2) The importance of continuous longitudinal nutritional assessment from diagnosis through survivorship
3) The role of nutrition on the well being of cancer survivors and chronic disease prevention
4) Incorporating nutritional research in survivorship research
View the YouTube video: https://youtu.be/Wk3dJ0rvJUY
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars: Subscribe today!
In this webinar:
Dr. Krista Noonan is a medical oncologist specializing in thoracic and genitourinary malignancies at BC Cancer, Surrey Centre. Her research interests focus on thoracic and genitourinary malignancies and health services research. On Thursday, February 27, join Dr. Noonan as she: - Reviews the advancements in systemic therapy in lung cancer over the past decade - Highlights how the advancements in systemic therapy have dramatically improved quality of life and length of life.
View the video: https://youtu.be/3DaUwQ8ab44
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don’t miss our upcoming webinars: Subscribe today!
The CanRehab Team brings together a large group of patients, researchers, and clinicians at four Canadian centres and includes three concurrent projects focused on improving access to effective, appropriate, and timely cancer rehabilitation (CanRehab Team).
The objectives of the presentation are: 1) to provide a background on cancer rehabilitation; 2) to introduce the CanRehab Team projects; and 3) to provide an overview of the team structure including a call for interest to the Patient Advisory Committee.
View the YouTube video: https://youtu.be/B2tcIsrw4WE
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars. Subscribe today!
Presented by: Marjut Huotari - Vice President, Healthcare Insights at Leger
In this webinar:
The Canadian Cancer Survivor Network commissioned Leger, a Canadian-owned polling and market research firm, to discover how the disruption of cancer care has affected Canadian cancer patients, survivors, and caregivers. This third survey Leger conducted for CCSN took place from June 10 to July 4, 2021.
Join CCSN and Leger as we present the results of the survey on COVID-19 and Cancer Care Disruption in Canada - Wave 3, and hear from members of the cancer community about how the pandemic has directly impacted them.
Watch the YouTube video: https://www.youtube.com/watch?v=CTomgU3AUSQ
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
During March, CCSN and patient advocates met with Alberta MLAs to discuss our COVID-19 and Care Care Disruption - Wave 2 Survey and the importance of prioritizing cancer patients in the vaccine rollout. In this webinar, we will hear from Tim Monds, a lung cancer patient advocate, share some outcomes from our meetings, discuss the key findings from our survey, and take a closer look at the Alberta data.
View the YouTube video: https://youtu.be/Tq5OJqA5_Rc
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
In this webinar:
In May-June, 2020, the Canadian Cancer Survivor Network (CCSN) commissioned Leger to conduct a national survey to evaluate the impact that COVID-19 has had on cancer patients, survivors, pre-diagnosis patients, and caregivers. The results of our first survey revealed that the pandemic response has triggered another public health crisis - the postponement and cancellation of essential cancer tests, procedures, and treatments.
CCSN commissioned Leger for a second survey in December, 2020 to evaluate the impact that the suspension of cancer services during the first wave is currently having on those who have been affected by cancer.
Join CCSN and Leger as we present the results of the COVID-19 and Cancer Care Disruption in Canada Survey - Wave 2 and hear from members of the cancer community about how the pandemic has directly impacted them.
View the YouTube video: https://youtu.be/qN4Hq7OtBys
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars. Subscribe today!
This presentation will highlight the promising new therapeutic strategies in the treatment of gliomas, with a focus on trials or therapies that will soon be available for Canadian patients.
View the YouTube video: https://youtu.be/ibbEuvSF7xY
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
In April, CCSN virtually met with MPPs throughout Ontario to discuss our COVID-19 and Cancer Care - Wave 2 Survey. During these meetings, we discussed the difficulty cancer patients and pre-diagnosis patients have had with accessing cancer services during the pandemic and the importance of ensuring the cancer patients receive their 1st and 2nd vaccine doses in a timely manner.
In this webinar, CCSN's Public Policy Analyst Conrad will begin by sharing some of the highlights from our meetings with Ontario MPPs. He will then turn things over to our patient advocates and they will share some of their reflections from our meetings as well as their own experiences with accessing cancer care during the pandemic. Lastly, Conrad will take a closer look at the Ontario data from our survey.
View the YouTube video: https://youtu.be/05u4i89WFfQ
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
Presented by: Dr. Poul Sorensen, MD, PhD, FRCPC; Dr. Muhammad Zulfiqar, MD; Ted Taylor, Patient Advocate
In this webinar, we will hear from Dr. Sorensen about his groundbreaking discovery and how it contributed to the development of tumour agnostic treatments. Dr. Zulfiqar, a medical oncologist at the BC Cancer Agency, will further discuss TRK fusion cancers and how he has been able to treat patients. Lastly, we will hear from Ted Taylor, a TRK fusion cancer patient diagnosed with glioblastoma (GBM) multiform being treated with Vitrakvi.
Watch the YouTube video: https://youtu.be/RAkItUeZ23Q
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars. Subscribe today!
In this webinar:
Attendees will learn about the role of exercise in the cancer care pathway, and the potential benefits from building a habit of moving more. We will also discuss the EXCEL study: EXercise for Cancer to Enhance Living Well, and how it is providing a sustainable exercise and behaviour change program to those living with cancer in rural and remote regions across Canada. Learn what is involved in this exercise research program and how to get involved online now!
View the YouTube video: https://youtu.be/BIOviCzESwA
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today.
In this webinar:
Our presenters will talk about the work the LAO does, provide information about the causes and symptoms of lymphedema, and inform lymphedema patients on how to access help and support. They will also include the physiotherapist perspective and discuss what treatments are available.
View the YouTube video: https://youtu.be/Wg1dzEOBPEA
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Take a deeper dive into the topic of Precision Medicine and what this means for colorectal cancer. This webinar is brought to you by Fight CRC’s Research Advocacy Training and Support (RATS) program.
On September 3, 2015, Ovarian cancer survivors and FDA Patient Representatives Peg Ford, Susan Leighton and Annie Ellis were invited to provide the patient perspective at the recent Ovarian Cancer Endpoints Workshop hosted by the Food and Drug Administration (FDA). This meeting was co-sponsored by the Society of Gynecologic Oncology (SGO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Many important topics to the ovarian cancer community were discussed, including novel clinical trial designs, biomarkers, and new classes of agents such as immunotherapies.
Cancer Survivorship: longer term issues and the role of primary care - Prof E...Irish Cancer Society
A presentation given at the Irish Cancer Society's Survivorship Research Day at the Aviva Stadium, Dublin on Thursday, September 20th, 2013.
Cancer Survivorship: longer term issues and the role of primary care - Prof Eila Watson (Oxford Brookes University).
Tonight’s speakers: Dr. Dan Sargent and Kim Ryan
Disclaimer: “This Report is not an official event of the 2012 Gastrointestinal Cancers Symposium. Not sponsored or endorsed by any of the cosponsoring organizations of the 2012 Gastrointestinal Cancers Symposium.”
Members of the Coleman Supportive Oncology Collaborative including over 169 cancer care providers from 44 institutions came together in person to share lessons from their 3-year project to improve supportive cancer care across the region and to launch the next step in the Coleman Foundation initiative which is to improve patient communication and experience.
Don't miss our upcoming webinars: Subscribe today!
In this webinar:
Dr. Paula Gordon will share information on when individuals should start screening for breast cancer, and how often to screen - in order for cancer to be found as early as possible, and to allow the least aggressive options for treatment. Dr. Gordon will also discuss how to screen for recurrence in women who’ve had cancer, explain why these methods are not always offered, and suggest what you can do to improve access to optimal screening.
View the video: https://youtu.be/7uFksz6_4Zk
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
Presented by: Dr. Paul C Rogers, MBChB, FRCPC, FRCP(Lond), MBA
In this webinar, Dr. Rogers will discuss:
1) Nutrition from a cancer control perspective
2) The importance of continuous longitudinal nutritional assessment from diagnosis through survivorship
3) The role of nutrition on the well being of cancer survivors and chronic disease prevention
4) Incorporating nutritional research in survivorship research
View the YouTube video: https://youtu.be/Wk3dJ0rvJUY
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars: Subscribe today!
In this webinar:
Dr. Krista Noonan is a medical oncologist specializing in thoracic and genitourinary malignancies at BC Cancer, Surrey Centre. Her research interests focus on thoracic and genitourinary malignancies and health services research. On Thursday, February 27, join Dr. Noonan as she: - Reviews the advancements in systemic therapy in lung cancer over the past decade - Highlights how the advancements in systemic therapy have dramatically improved quality of life and length of life.
View the video: https://youtu.be/3DaUwQ8ab44
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don’t miss our upcoming webinars: Subscribe today!
The CanRehab Team brings together a large group of patients, researchers, and clinicians at four Canadian centres and includes three concurrent projects focused on improving access to effective, appropriate, and timely cancer rehabilitation (CanRehab Team).
The objectives of the presentation are: 1) to provide a background on cancer rehabilitation; 2) to introduce the CanRehab Team projects; and 3) to provide an overview of the team structure including a call for interest to the Patient Advisory Committee.
View the YouTube video: https://youtu.be/B2tcIsrw4WE
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars. Subscribe today!
Presented by: Marjut Huotari - Vice President, Healthcare Insights at Leger
In this webinar:
The Canadian Cancer Survivor Network commissioned Leger, a Canadian-owned polling and market research firm, to discover how the disruption of cancer care has affected Canadian cancer patients, survivors, and caregivers. This third survey Leger conducted for CCSN took place from June 10 to July 4, 2021.
Join CCSN and Leger as we present the results of the survey on COVID-19 and Cancer Care Disruption in Canada - Wave 3, and hear from members of the cancer community about how the pandemic has directly impacted them.
Watch the YouTube video: https://www.youtube.com/watch?v=CTomgU3AUSQ
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
During March, CCSN and patient advocates met with Alberta MLAs to discuss our COVID-19 and Care Care Disruption - Wave 2 Survey and the importance of prioritizing cancer patients in the vaccine rollout. In this webinar, we will hear from Tim Monds, a lung cancer patient advocate, share some outcomes from our meetings, discuss the key findings from our survey, and take a closer look at the Alberta data.
View the YouTube video: https://youtu.be/Tq5OJqA5_Rc
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
In this webinar:
In May-June, 2020, the Canadian Cancer Survivor Network (CCSN) commissioned Leger to conduct a national survey to evaluate the impact that COVID-19 has had on cancer patients, survivors, pre-diagnosis patients, and caregivers. The results of our first survey revealed that the pandemic response has triggered another public health crisis - the postponement and cancellation of essential cancer tests, procedures, and treatments.
CCSN commissioned Leger for a second survey in December, 2020 to evaluate the impact that the suspension of cancer services during the first wave is currently having on those who have been affected by cancer.
Join CCSN and Leger as we present the results of the COVID-19 and Cancer Care Disruption in Canada Survey - Wave 2 and hear from members of the cancer community about how the pandemic has directly impacted them.
View the YouTube video: https://youtu.be/qN4Hq7OtBys
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars. Subscribe today!
This presentation will highlight the promising new therapeutic strategies in the treatment of gliomas, with a focus on trials or therapies that will soon be available for Canadian patients.
View the YouTube video: https://youtu.be/ibbEuvSF7xY
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
In April, CCSN virtually met with MPPs throughout Ontario to discuss our COVID-19 and Cancer Care - Wave 2 Survey. During these meetings, we discussed the difficulty cancer patients and pre-diagnosis patients have had with accessing cancer services during the pandemic and the importance of ensuring the cancer patients receive their 1st and 2nd vaccine doses in a timely manner.
In this webinar, CCSN's Public Policy Analyst Conrad will begin by sharing some of the highlights from our meetings with Ontario MPPs. He will then turn things over to our patient advocates and they will share some of their reflections from our meetings as well as their own experiences with accessing cancer care during the pandemic. Lastly, Conrad will take a closer look at the Ontario data from our survey.
View the YouTube video: https://youtu.be/05u4i89WFfQ
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today!
Presented by: Dr. Poul Sorensen, MD, PhD, FRCPC; Dr. Muhammad Zulfiqar, MD; Ted Taylor, Patient Advocate
In this webinar, we will hear from Dr. Sorensen about his groundbreaking discovery and how it contributed to the development of tumour agnostic treatments. Dr. Zulfiqar, a medical oncologist at the BC Cancer Agency, will further discuss TRK fusion cancers and how he has been able to treat patients. Lastly, we will hear from Ted Taylor, a TRK fusion cancer patient diagnosed with glioblastoma (GBM) multiform being treated with Vitrakvi.
Watch the YouTube video: https://youtu.be/RAkItUeZ23Q
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars. Subscribe today!
In this webinar:
Attendees will learn about the role of exercise in the cancer care pathway, and the potential benefits from building a habit of moving more. We will also discuss the EXCEL study: EXercise for Cancer to Enhance Living Well, and how it is providing a sustainable exercise and behaviour change program to those living with cancer in rural and remote regions across Canada. Learn what is involved in this exercise research program and how to get involved online now!
View the YouTube video: https://youtu.be/BIOviCzESwA
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Don't miss our upcoming webinars! Subscribe today.
In this webinar:
Our presenters will talk about the work the LAO does, provide information about the causes and symptoms of lymphedema, and inform lymphedema patients on how to access help and support. They will also include the physiotherapist perspective and discuss what treatments are available.
View the YouTube video: https://youtu.be/Wg1dzEOBPEA
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Take a deeper dive into the topic of Precision Medicine and what this means for colorectal cancer. This webinar is brought to you by Fight CRC’s Research Advocacy Training and Support (RATS) program.
On September 3, 2015, Ovarian cancer survivors and FDA Patient Representatives Peg Ford, Susan Leighton and Annie Ellis were invited to provide the patient perspective at the recent Ovarian Cancer Endpoints Workshop hosted by the Food and Drug Administration (FDA). This meeting was co-sponsored by the Society of Gynecologic Oncology (SGO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Many important topics to the ovarian cancer community were discussed, including novel clinical trial designs, biomarkers, and new classes of agents such as immunotherapies.
Cancer Survivorship: longer term issues and the role of primary care - Prof E...Irish Cancer Society
A presentation given at the Irish Cancer Society's Survivorship Research Day at the Aviva Stadium, Dublin on Thursday, September 20th, 2013.
Cancer Survivorship: longer term issues and the role of primary care - Prof Eila Watson (Oxford Brookes University).
Tonight’s speakers: Dr. Dan Sargent and Kim Ryan
Disclaimer: “This Report is not an official event of the 2012 Gastrointestinal Cancers Symposium. Not sponsored or endorsed by any of the cosponsoring organizations of the 2012 Gastrointestinal Cancers Symposium.”
Members of the Coleman Supportive Oncology Collaborative including over 169 cancer care providers from 44 institutions came together in person to share lessons from their 3-year project to improve supportive cancer care across the region and to launch the next step in the Coleman Foundation initiative which is to improve patient communication and experience.
Beginning this fall, Komen Greater NYC is mounting an ambitious initiative to explore the issues, examine the programs that are working, and propose solutions to making this vital piece of the healthcare puzzle available for all New Yorkers.
An Interactive Discussion On Key Issues Affecting Young Adult Colorectal Cancer Patients and Their Caregivers
Powered By Our Survivor Community and Their Families
EOA2016: Connecting Community to the Delivery System PublicPIHCSnohomish
During the last breakout session of the day, at Edge of Amazing 2016, a panel came together to discuss the interdependencies that are not the responsibility of any single organization, but are required if we want to achieve population health. They featured the many ways community is linking to the delivery system, including an overiew of the Plan for Improving Population Health and the Practice Transformation Support Hub.
Mary Beth Brown, WA State DOH
Maria Courogen, WA State DOH
Dr. Gary Goldbaum, Snohomish Health District
Linda McCarthy, Mt. Baker Planned Parenthood
Elevate Leads the Way for a Better Cancer Survivorship Experience For Survivo...linda brown
Survivors face many challenges, and our health care system simply isn’t geared to help people live well after the treatments are completed. As treatments improve and people with cancer live longer, more attention needs to be paid to their future health needs to improve the quality of life in survivorship. To know more, visit:
AHRQ's Health Care Innovations Exchange held a Web Seminar on Linking Clinical Care and Communities for Improved Prevention on September 1, 2011. For more information, visit https://innovations.ahrq.gov/events/2011/09/linking-clinical-care-and-communities-improved-prevention.
Colorectal Cancer Awareness Month may be behind us, but that doesn't mean our efforts to increase screening rates will slow down! Join Mary Doroshenk, MA, to learn about initiatives to increase colorectal cancer screening nationwide! In this webinar, designed for all those touched by colorectal cancer, Mary will discuss what 80% by 2018 is and how the effort is working. She will explain the role of survivors and caregivers and inspire you to participate in the effort.
Welcome to the "Health Communication Matters! The Ongoing Challenge to Implement the Affordable Care Act" webinar sponsored by the California Pacific Public Health Training Center (CALPACT) at UC Berkeley's School of Public Health.
The most sweeping health policy change in decades – the Affordable Care Act, has created a myriad of challenges in how to convey a complex subject to the public, the media, policymakers, and other professionals. Experts in ACA-related health literacy and health insurance literacy initiatives walk us through ongoing areas of challenge after the passage of the ACA and health communication principles to deliver understandable and compelling content to diverse audiences.
Follow Us on Twitter: @CALPACT
Facebook: http://www.facebook.com/CALPACTUCB
Website: www.calpact.org
5th Annual Early Age Onset Colorectal Cancer - Session V: Part I - How Did This Happen? Investigating the Causes of Early Onset Colorectal Cancers (EAOCRC) The Genetics of Heritable CRC: What's New and Important to Know Regarding the Genetics of EAOCRC?
5th Annual Early Age Onset Colorectal Cancer - Session VI: Palliative Care: Why Early is Best Including Guidance, Support and Resources to Patients and Caregivers During Their Treatment Journey/Continuum of Care. Epigenetics and its Future Role in the Diagnosis and Treatment of Individuals More Specifically and Accurately.
An Interactive Discussion On Key Issues Affecting Young Adult Colorectal Cancer Patients and Their Caregivers
Powered By Our Survivor Community and Their Families
An Interactive Discussion On Key Issues Affecting Young Adult Colorectal Cancer Patients and Their Caregivers
Powered By Our Survivor Community and Their Families
This ground breaking program provided both survivors and health care professionals the opportunity to leverage each other's insights and an opportunity for all to hear "state-of-the-science" presentations on the epidemiology, pathogenesis, genomics and optimal multidisciplinary care of EAO-CRC.
The 2016 EAO CRC Summit featured keynote addresses from leading clinicians, epidemiologists and researchers from Europe, Africa, Australia and the nation's leading cancer centers and advocacy organizations.
The Early Age Onset (EAO) Colorectal Cancer (CRC) Summit was a novel meeting designed for Early Age Onset (EAO) colorectal cancer (CRC) survivors, affected families as well as physicians and scientists who were interested in advancing their understanding of the rapidly increasing incidence of rectal and colon cancer among young adults under 50 years of age.
Co-hosted by the Colon Cancer Challenge Foundation and the CME office of Memorial Sloan Kettering Cancer Center the program provided an opportunity to hear leading clinicians and scientists on the epidemiology, pathogenesis, genomics and lifestyle challenges of EAO-CRC.
The course also included lectures as well as workshops and panel discussions designed to facilitate multidisciplinary consensus regarding the priorities of EAO-CRC prevention, clinical care and research moving forward.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
5th Annual Early Age Onset Colorectal Cancer - Session I
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53. 1. Survivor Introductory Comments Frame EAO-CRC 2019
2. Progress 2018
3. Applying EAO-CRC 2019 to Reducing Young Adult CRC Incidence and
Mortality
Thomas Weber, MD FACS
Professor of Surgery and Epidemiology
Donald & Barbara Zucker School of Medicine at Hofstra / Northwell
Director, Surgical Oncology, Northwest Region
Northwell Health, NY, USA
54. 1. Survivor Introductory Comments Frame EAO-CRC 2019
2. Progress 2018
3. Applying EAO-CRC 2019 to Reducing Young Adult CRC Incidence and
Mortality
Thomas Weber, MD FACS
Professor of Surgery and Epidemiology
Donald & Barbara Zucker School of Medicine at Hofstra / Northwell
Director, Surgical Oncology, Northwest Region
Northwell Health, NY, USA
55. 1. Survivor Introductory Comments Frame EAO-CRC 2019
2. Progress 2018
3. Applying EAO-CRC 2019 to Reducing Young Adult CRC Incidence and
Mortality
• Survivor Survey Results
• NCCRT Risk Assessment Tool Kit : Implementation Progress
• Report on the NCCRT, Colon Cancer Foundation, EIF Bethesda
Strategic Retreat. Jan Lowery PhD.
• American Cancer Society Revised (Earlier Age) CRC Screening
Guidelines. Robert Smith, PhD ACS
• NCI and International funded EAO Research Initiatives
• Novel Causation Research Initiatives
• EAO-CRC 2019 Action Plan & Network
56. 1. Survivor Introductory Comments Frame EAO-CRC 2019
2. Progress 2018
3. Applying EAO-CRC 2019 to Reducing Young Adult CRC Incidence and Mortality
• A Strategic Shift! A Change in Tone.
• EAO-CRC 2019 as a Road Map / Blue Print for Action & Progress.
• As You Review Each Section of the Program; You Can See; Each of the Primary Components of an
Effective, Successful EAO-CRC Prevention, Earliest Possible Diagnosis, Optimal Fertility Preserving
Treatment and Causation Research Program are Presented.
• An Academic Step Up: Submission, Review and Presentation of Original Research Posters. Susan
Peterson PhD
• You will also see in your folders the “National Clinical Alert: Young Adult Colorectal Cancer”. A set of
Guidelines for Providers, Institutions and Health Care Systems to Use to Effectively Address the EAO-CRC
Problem. This document “Alerts” Providers to the EAO-CRC problem and provides clear guidance on how
to effectively address the problem and save lives. Presented By Drs. Albert, Boet, Jones and Erin
Peterson. This will be published and promoted nationally / internationally
• There will also be a Published Report of the proceedings of EAO-CRC 2019.
• We will launch the EAO-CRC Action NetworkTM
• Pretty much everything YOU, Your Hospital and the NATION needs to organize an effective EAO-CRC
Prevention, Earliest Possible Diagnosis, Age Appropriate Treatment and Causation Research Program is
outlined here.
• So, take notes, ask questions, go forth and do what needs to be done and stay in touch! There is
strength and increased probability of success in numbers.
58. 58
ACCREDITATION
This live activity has been planned and implemented in
accordance with the Essential Areas and Policies of the
Accreditation Council for Continuing Medical Education through
the joint sponsorship of Northwell Health and The Colon Cancer
Foundation. Northwell Health is accredited by the Accreditation
Council for Continuing Medical Education to provide Continuing
Medical Education for physicians.
CREDIT DESIGNATION
Northwell Health designates this live Educational activity for a
maximum of 11.0 AMA PRA Category I credits TM. Physicians
should only claim credit commensurate with the extent of their
participation in the activity.
Northwell Health
59. 59
SIGN-IN
To receive either CME or Verification of Attendance
Certificates, you must sign in at the registration desk.
Please make sure to verify your correct email address.
Please note that if you leave early, you can only claim
credit for the number of hours you actually attend.
60. 60
EVALUATIONS AND
OUTCOMES SURVEY
Evaluations and the 3 month post activity outcomes
survey for this activity will be conducted through Survey
Monkey. Please look for the email that will have the link to
the survey. Your cooperation in completing the survey in a
timely manner will be appreciated. Once the evaluation is
completed, you will be routed to your CME certificate.
Please be sure that you have provided the correct email
address for the survey.
61. 61
DISCLOSURE POLICY
Northwell Health adheres to the ACCME’s Standards for
Commercial Support. Any individuals in a position to control
the content of a CME activity, including faculty, planners,
reviewers or others are required to disclose all financial
relationships with commercial interests. All relevant conflicts
of interest will be resolved prior to the commencement of
the activity.
62. 62
FACULTY DISCLOSURES
The following faculty, moderators, planners and managers have nothing to disclose:
NAME ROLE IN ACTIVITY
Andrew Albert MD, MPH Presenter
Irit
Ben-
Aharon MD, PhD Presenter
Semir Beyaz PhD Presenter
Chelsea Boet MD Presenter
Jennifer Brown PhD Presenter
Yin Cao MPH, ScD, MPH Presenter
Tabitha Cavanagh Presenter
Andrea Cercek MD Presenter
Zana Correa NP Presenter
Sarah Debord Presenter
63. 63
FACULTY DISCLOSURES
The following faculty, moderators, planners and managers have nothing to disclose:
NAME ROLE IN ACTIVITY
James T. D'Olimpio
MD, FACP,
FAAHPM Moderator
Cathy Eng
MD, FACP,
FASCO Presenter
Andy Eshe MD, MBA Presenter
Karen Fasciano PsyD Presenter
Gregory Feero MD, PhD Moderator
Tony Foleno Presenter
Kevin Hays DDS, PhD, MPH Presenter
Richard Hayes Presenter
Wes Hensel MD Presenter
Steven H. Itzkowitz MD Presenter
64. 64
FACULTY DISCLOSURES
The following faculty, moderators, planners and managers have nothing to disclose:
NAME ROLE IN ACTIVITY
Whitney Jones Moderator
Jordan Karlitz Presenter
Noah D Kauff Moderator
Sayoni Lahiri MS, CGC Presenter
Xavier Llor MD, PhD Presenter
Jan Lowery PhD Presenter
Christine L. Molmenti PhD, MPH Presenter
Kimmie Ng MD, MPH Presenter
Nicole Noyes MD Presenter
Jose Perea MD, PhD Presenter
Susan Pfau MA Presenter
65. 65
FACULTY DISCLOSURES
The following faculty, moderators, planners and managers have nothing to disclose:
NAME ROLE IN ACTIVITY
Erin Peterson Presenter
Eric Reddy Presenter
Rebecca L. Siegel MPH Presenter
Robert Smith Presenter
Diana Sloan Presenter
Zsofia Stadler Presenter
Elena Stoffel MD, MPH Presenter
Denelle Suranski Presenter
Kana Wu MD, PhD Presenter
Susan Wyzoki Presenter
Ronit Yardin PhD, MHSA Presenter
Matthew B. Yurgelun MD Presenter
66. 66
FACULTY DISCLOSURES
The following reviewers, planners and managers have nothing to disclose:
NAME ROLE IN ACTIVITY
Richard Barakat MD Planning Committee
Wasif Saif MD Course Co-Director
Cindy Borassi Planning Committee
Susan K. Peterson MS, LGC Course Co-Director
Thomas Weber MD, FACS Course Director
Mary B. Strong MA Planning Committee
Krista Nelson LCSW, OSW-C,
BCD, FAOSW
Planning Committee
67. 67
FACULTY DISCLOSURES
Dennis Ahmen, MD, AGAF, FACG – Moderator/Presenter
Discloses that he receives honorarium from Ambry Genetics for speaking and
receives honoraria from Cancer Prevention Pharmaceuticals as a member of
their Data and Safety Monitoring Committee
Jordan Karlitz, MD, FACG
Discloses that he receives honorarium from Exact Sciences as an Advisor and
honorarium from Myriad Genetics for consulting services and as a member of their
speakers bureau.
C. Richard Boland, MD – Presenter
Discloses that he receives financial support from Ambry Genetics for teaching.
Whitney Jones, MD – Moderator
Discloses that she receives honoraria and consulting fees as a speaker for Myriad Genetics.
68. 68
FACULTY DISCLOSURES
Zsofia K. Stadler, MD
Discloses that her spouse has a consultant/advisory role with Allergan, Adverum
Biotechnologies, Alimera Sciences, Biomarin, Fortress Biotech, Genentech, Novartis, Optos,
Regeneron, Regenxbio and Spark Therapeutics.
Heather Hampel, MS, LGC – Moderator
Discloses that she receives grant research support as a PI from Myriad Genetics, honoraria
from Beacon LBS as a Consultant, receives honoraria and is a stock/shareholder as an
Advisory Board Member for Genome Medical. She also receives honoraria from Invitae as an
Advisory Board Member.
Noah D. Kauff, MD
Discloses that he honoraria from BGI for giving lectures, consulting fees from AstraZeneca as
PI and consulting fees from Merck as PI.
69. 69
Acknowledgements
The Colon Cancer Foundation and Northwell Health gratefully acknowledge
the exhibit sponsorship provided to support this activity by:
The Northwell Health Cancer
Institute
70. 70
Acknowledgements
The Colon Cancer Foundation and Northwell Health gratefully acknowledge the
exhibit sponsorship provided to support this activity by:
LUC WALTER
71. 71
Acknowledgements
The Colon Cancer Foundation and Northwell Health gratefully acknowledges
the exhibit sponsorship provided to support this activity by:
BRACCO DIAGNOSTICS
72. 72
Acknowledgements
The Colon Cancer Foundation and Northwell Health gratefully acknowledges
the exhibit sponsorship provided to support this activity by:
never too young
Colorectal Cancer Alliance
73. 73
Acknowledgements
The Colon Cancer Foundation and Northwell Health gratefully acknowledge
the exhibit sponsorship provided to support this activity by:
`
Advanced Surgery Center
of Long Island
Advanced Endoscopy
Center
Colon Cancer Coalition Carnegie Hill Endoscopy
The Endoscopy Center of
New York
Epigenomics/Epi pro colon
74. 74
Acknowledgements
The Colon Cancer Foundation and Northwell Health gratefully acknowledge
the exhibit sponsorship provided to support this activity by:
East Side Endoscopy Liberty Endoscopy
Manhattan Endoscopy Merck
Myriad Physicians Endoscopy
Quest Diagnostics
75. 75
Acknowledgements
The Colon Cancer Foundation and Northwell Health gratefully acknowledge
the exhibit sponsorship provided to support this activity by:
AliveAndKickn Boston Scientific
Medtronic Olympus
76. 76
COURTESY REMINDER
Please set cell phones and electronic devices to silent mode,
or turn them OFF.
WIFI Network: Marmorino
Password: orange21
There are few outlets throughout the building so to help keep
everyone connected we have set up a charging station outside the
auditorium near the snack station.
77. 77
COURTESY REMINDER
You have a printed Agenda in your folder as well as a digital Course Journal
online which includes the Agenda, Faculty Bios and a Summary of the abstracts.
It can be found at https://coloncancerfoundation.org/agenda
We will be following this agenda very closely and ask our distinguished faculty to
be aware of the time clock at the back of the room and the signs that will be
held up to remind you of your time remaining. If you run over you will hear
progressively louder reminders that your time is UP!
We also ask our phenomenal participants to be mindful of the time and duration
of breaks/lunch and to do their best to make it back to their seats on time.
We welcome the entire audience, Faculty, Exhibitors and Participants, to be
thoroughly engaged in the Strategic Planning Discussions following each Session
and on Day 2. Your opinion matters!
Bathrooms are located down the stairs and to the right.
80. International Colon Cancer (C18) Incidence Trends to 2015: Ages 20-49?
Cancer Incidence in 5 Continents, International Association of Cancer
Registries and the International Agency for Research on Cancer
Thomas Weber, MD FACS
Professor of Surgery and Epidemiology
Donald & Barbara Zucker School of Medicine at Hofstra / Northwell
Director, Surgical Oncology, Northwest Region
Northwell Health, NY, USA
81. International Colon Cancer (C18) Incidence Trends to 2014? Ages 20-49
Cancer Incidence in 5 Continents, International Association of Cancer Registries and the
International Agency for Research on Cancer
82. What is the Global CRC Situation?
&
What Can We learn From That Data?
83. • “Understanding the current
patterns of CRC presentation
and its evolution from an
International Perspective is
imperative in order to direct
future prospects of reducing
the burden through cancer
prevention and care”
93. 93
Patterns and trends in early-onset
colorectal cancer in the United States
Rebecca Siegel, MPH
EAO CRC Summit
May 2, 2019
94. Trends in CRC incidence by age, 1975-2016
50+ years
0
50
100
150
200
250
300
1975 1980 1985 1990 1995 2000 2005 2010 2015
Casesper100,000
Year of diagnosis
20-49 years
0
3
6
9
12
15
1975 1980 1985 1990 1995 2000 2005 2010 2015
Year of diagnosis
Men
Men
Women
Women
96. State variation in early-onset CRC in the U.S., 1995-2015
96
Data sources
North American Association of Central Cancer Registries (47 states), 1995-2015
Behavioral Risk Factor Surveillance System, 1995-2005
Population
Adults aged 20-49 years stratified by race/ethnicity
Measures
State-level changes in
CRC incidence, 2006-2015
Obesity prevalence (BMI>30 kg/m2)
Heavy alcohol consumption (>14 and >7 drinks/week in men and women, respectively)
98. 98
Early-onset CRC incidence rates by state, NHW, 2011-2015
14.3
8.7
DC, 8.2
Incidence rates are per 100,000 population and age-standardized.
99. Changes in Early-onset CRC incidence by state, NHW, 2006-2015
AAPC=Average annual percent change in incidence rates during 2006 to 2015
40/47
states
100. 0
1
2
3
4
5
6
7
8
1995 2000 2005 2010 2015
Casesper100,000
Year of diagnosis
Colorado
Colon
AAPC, 4.2
Convergence of colon & rectal cancer rates in NHWs
AAPC, 1.5
Rectum Nevada
Utah
101. 101
Are changes in obesity correlated with changes in CRC?
Obesity 1995 2005
vs
CRC 2006 2015
103. 103
Murphy et al. Gastroenterology 2017
“There's also a scenario in which this seemingly
glum cancer trend is in fact good news.”
Richard Harris, National Public Radio, Feb 2017
104. Are temporal trends in colonoscopy use concordant with
CRC incidence in young adults?
104
Data sources
National Health Interview Survey, 2000-2015
Surveillance, Epidemiology, & End Results Program, 2000-2015
Population
Adults aged 40-49 years
Measures
Changes in
past-year colonoscopy use
CRC incidence
106. 106
Casesper100,000
APC, 1.7*
APC, 1.1*
CRC incidence, ages 40-49 yrs, 2000-2015
40-44 years 45-49 years
*Annual percent change is statistically significantly different from zero (P<0.05)
107. Early-onset CRC by stage at diagnosis
40-44 years 45-49 years
Localized APC, 1.1*
Distant APC, 2.9*
Localized APC, 0.4
Distant APC, 2.3*
*Annual percent change is statistically significantly different from zero (P<0.05)
108. 108
Trend in CRC mortality among adults 20-49 yrs, 1970-2017
Year of death
Deathsper100,000
2004-2017 APC, 1.3*
Year of death
2004-2017 APC, 1.8*
All races White
*Annual percent change is statistically significantly different from zero (P<0.05)
109. Summary & Conclusion
• Increase in CRC malignancies due to changes in exposure in addition to obesity and alcohol?
• Steepest increase:
Youngest generations
Rectum
Non-Hispanic whites
Western states – healthier lifestyles
• Highest rates in the South
3,600 CRC deaths in people 20-49 years in 2017
112. Utilization of CDC Comparative
Effectiveness Research Data to
Assess Lynch Syndrome Screening
Practices and Surgical Management
in Early-onset Colorectal Cancer
Jordan J. Karlitz, MD
Associate Professor of Medicine
Director,
GI Hereditary Cancer and Genetics Program
Division of Gastroenterology, Tulane University School of Medicine
114. Objectives
– Review components CDC Comparative Effectiveness Research (CER) Data set
• Potential utility in using CER data to study EOCRC, understand rising EOCRC rates etc.
– Example of using CER data to understand population-based Lynch Syndrome
screening and surgical management practices
• Highlights detailed/granular nature of CER data set
115. CER Data Overview
• CER definition:
– “The generation and synthesis of evidence that compares the
benefits and harms of alternative methods to prevent, diagnose,
treat, and monitor a clinical condition or improve the delivery of
care”
• Funding available to CDC for data collection in 2011 only
• CDC established 10 specialized registries within National
Program of Cancer Registries (NPCR) to participate
• AK, CO, ID, LA, NH, NC, RI, TX, CA (parts), FL (parts)
• Focused on 4 cancers—breast, colon, rectum and CML
• CER=largest and most comprehensive data collection effort
by population-based registries in the U.S.
Chen, V.W., et al., Enhancing Cancer Registry Data for Comparative Effectiveness
Research (CER) Project: Overview and Methodology. J Registry Manag, 2014.
41(3):103-12.
116. CER Data Overview
• CER:
– enhanced data collection (compared to usual registry practice) of
cancer treatment, biomarkers (KRAS, MSI etc.), height, weight,
smoking status, comorbidities, insurance coverage, income level etc.
• Training provided by CDC to state registries and registry
abstractors to standardize data collection processes
• Hospital registrars, or central registry abstractors who directly
visited facilities, collected data and fed back to state registry
• Data collected from hospital and out-of-hospital sites
117. CER Data Overview
• 75,042 cancer patients
• 64.6% breast cancer, 24.5% colon cancer, 9.5% rectal cancer,
1.4% CML
• Colon cancer 18,143 cases
• Rectal cancer 7,129 cases
• 1709 colon cancer patients <50
• 1049 rectal cancer patients <50
118. Example of CER dataset utilization
LA incidence 46.5/100,000 (4th highest in U.S.)
U.S. incidence 39.2/100,000
119. Colorectal Cancer Incidence Rate: Louisiana, 2010-2014
Age 50-74
Created by Louisiana Tumor Registry, 03/01/2017.
Standardized Incidence Ratio is calculated as the incidence rate in the local area relative to the state-wide rate for a 5-year period.
They are age-adjusted according to US standard 2000 population. This map shows the SIRs for 1148 overlapping circular areas centered on
the census tract centroids and each area contains around 20,000 populations and at least 21 cases.
Standardized Incidence Ratio (SIR)
Percentile Rank (1148 census tracts)
<=11% percentile (0.8)
<=22% percentile (0.88)
<=33% percentile (0.92)
34%-66% percentile
>=67% percentile (1.04)
>=78% percentile (1.1)
>=89% percentile (1.19)
Acadian Region (? Lynch syndrome founder effect)
Geospatial Analysis, Census Tract Analysis: LTR Data
-Incidence rate in local area compared to statewide rate
-1148 census tracts vs 64 parishes
120. Lynch Syndrome
• 1:300 in U.S. mutation carriers, many undiagnosed (> 1 million people)
• Autosomal Dominant, up to 80% lifetime risk of CRC
• Tumor testing with MSI and/or IHC
https://www.cancer.net/cancer-types/lynch-syndrome
121. Use CER data to assess abnormal MSI/IHC test
results in Acadian Region
• Biomarker data existed, but testing rates so low that would not
help understand potential hereditary burden of CRC in region
• Shift gears and study population-based testing practices in
Louisiana (quality of care)
123. Underutilization of LS screening
• CDC CER Data focused on Louisiana Tumor Registry
• First population-based study examining LS screening practices in U.S.
• All patients ≤ age 50 in Louisiana diagnosed with CRC in 2011 (274
patients)
• Care at 61 distinct health care facilities
• LS screening rate with MSI and/or IHC only 23% (should be 100%)
Karlitz JJ et al: Population-based Lynch Syndrome screening
by microsatellite instability in patients ≤50: prevalence, testing determinants,
and result availability prior to colon surgery. Am J Gastroenterol. 2015 Jul;110(7):948-55
124. Variables associated with the ordering of MSI
and/or IHC testing
% Testing Unadjusted OR Adjusted OR
Hospital Type
THCP 16.7% *0.30 (0.11-0.77) 0.55 (0.18-1.63)
COMP 40.4% Ref Ref
CHCP 17.0% *0.31 (0.10-0.83) 0.62 (0.20-1.88)
Public 6.5% *0.10 (0.01-0.48) *0.17 (0.04-0.77)
Non-CoC/Non-
Public
24.7% 0.49 (0.22-1.07) 0.92 (0.39-2.17)
1st Degree
relative CRC
Yes 48.0% *2.98 (1.21-7.33) *2.76 (1.03-7.40)
No 23.6% ref ref
CHCP, community hospital cancer program
CoC, Commission on Cancer
COMP, community hospital comprehensive cancer program
THCP, teaching hospital cancer program
125. Variables associated with the ordering of MSI and/or IHC
testing
% Testing Unadjusted OR Adjusted OR
Region
Region 1 16.4% Ref Ref
Region 2 35.1% *2.76 (1.24-6.16) *2.88 (1.13-7.35)
Region 3 19.5% 1.24 (0.57-2.69) 1.67 (0.67-4.13)
Urban/Rural
Urban 25.9% Ref Ref
Rural 12.3% *0.40 (0.19-0.87) 0.49(0.21-1.12)
Region 1=Includes state’s academic medical centers and surrounding areas (12 parish region)
Region 2=State capital region and surrounding areas (11 parish region) (Pennington
Biomedical Research Center-genomics focus).
Region 3=All other parishes in Louisiana
126. Timing of MSI/IHC testing
• Preoperative testing on colonoscopy biopsy
specimen (as opposed to CRC surgical resection)
can help guide germline testing and extent of
colonic resection
• High metachronous CRC rates in LS in segmental
resection
• If MSI/IHC done on surgical resection specimen,
results return after operation (no opportunity
for risk/benefit discussion of extent of surgery)
127. Timing of MSI/IHC testing
• MSI and/or IHC results available preoperatively in only 16.9%
of cases.
–Testing ordered on colonoscopy specimen only 34.9% of the
time
–Even if done on colonoscopy, some patients go to OR
without waiting for results to return
–Ordered on surgical specimen 61.9% of the time
128. IHC results
- Of the 60 patients tested for MSI and/or IHC who had available results,
13 out of 60 patients (21.7%) had abnormal results.
- Of the 8 patients with abnormal IHC, 7 (87.5%) had a pattern that would be consistent
with LS
129. Extended Colonic Resection Study
Karlitz JJ et al. Factor Associated with the Performance of Extended Colonic Resection vs.
Segmental Resection in Early-Onset Colorectal Cancer: A Population-based Study. Clinical
Transl Gastro, 2016.
130. Results
• Same early-onset cohort in Louisiana.
• Only 6.8% underwent extended colonic resection (ECR).
• ECR not associated with abnormal MSI/IHC results.
– Abnormal test results most commonly available post-operatively so
do not know LS risk pre-op.
• ECR associated with polyposis and age < 45.
131. 2018-National Survey of GIs Through ACG Mailing List-Why are
MSI/IHC Testing Rates So Low?
Use LA CER
data as a jumping
off point to
understand
what is happening
nationally.
Noll A, Parekh PJ, Zhou M, Weber TK, Ahnen D, Wu XC, Karlitz JJ. Barriers to Lynch Syndrome Testing
and Preoperative Result Availability in Early-onset Colorectal Cancer: A National Physician Survey Study
Clinical Transl Gastro, October 2018.
132. Goals of Study
• What are barriers to ordering MSI/IHC?
• What are barriers to preoperative result availability?
• 5786 confirmed ACG questionnaire recipients by email.
• 509 took survey (8.7% response rate).
133. Barriers to Test Ordering
• Cost of testing (33.3%).
• Unfamiliarity interpreting results (29.2%).
• Unavailable genetic counseling (24.9%).
• Non-academic and rural settings associated with cost and
genetic counseling barriers.
134. Inconsistencies in who is felt should order
MSI/IHC may lead to diffusion of responsibility,
preventing consistent testing (assume others
ordering when they are not)
135. Conclusions
• SEER data used to identify high-risk Acadian population (? Lynch syndrome founder
effect)
• CER data unable to be used to understand potential genomic burden due to low
MSI/IHC testing rates
• CER data able to be used to obtain granular understanding of Lynch syndrome
management practices on a population-based level (testing rates, surgical
management)
• Potential future applications of utilizing CER data set to be understand EOCRC (2011
data on 2758 CRC patients <50)
136. Overview of European Cancer
Registries Data Resources:
Early Onset CRC
Irit Ben-Aharon MD, PhD
Head, Division of Oncology
Rambam Health Care Campus,
Haifa, Israel
Head, Young-onset Task Force, GI Group, EORTC
138. Statistics:
Digestive tract Cancer
Long-Term Trends in SEER
Incidence Rates, 1975-2015
<50y
http://seer.cancer.gov/statfacts/html/
Colorectal Cancer
Long-Term Trends in SEER
Incidence Rates, 2000-2015
<50y
139. • ENCR – European, Network of Cancer Registries
Network since 1990, collaboration between cancer registries
Cancer incidence and mortality in Europe
• WHO – World Health Organization
153. Conclusions:
The trend observed is not homogenous:
Increased incidence in Western Europe
Mixed trends in Middle Europe
Stable trend in Mediterranean countries
Stable trends in the Far East
154. Obesity
Antibiotic use
Diet?
Ethnicity?
Potential contributors:
What is the role of epigenetic modifications?
156. Survey of Young-Onset Patients,
Survivors, and Caregivers: Self-
Reported Clinical, Psychosocial,
Financial and Quality of Life
Experiences
Ronit Yarden, PhD, MHSA
Director of Medical Affairs
157. Patients’ Demographics
Patient and Survivor Characteristics
N=1195
Sex (No.)
Females 976
Males 219
Type of Cancer
Colon Cancer 875
Rectal Cancer 315
Race / Ethnicity (No.)
White Caucasians 1045
Hispanic / Latino 60
African Americans 49
Asians / Pacific Islanders 23
Native Americans 14
Others 4
Age at Diagnosis (No.)
<20 5
20-29 112
30-39 393
40-49 684
US=1090
158. Patients’ Reported Symptoms and
Their Duration Prior to Diagnosis%ofPatients
Time Before Reaching Out
to a Physician
159. Saw 1 Dr.
33%
Saw 2 Drs.
40%
Saw 3 Drs.
16%
Saw 4 Drs. or more
11%
67%
Young-Onset Patients Visited Multiple
Physicians Prior to Diagnosis
17%
ER
50%
Misdiagnosed
0
10
20
30
40
50
%ofPatientsandSurvivors
p<0.001
p<0.03
p<0.01
p<0.009
20-29
20-29
30-39
30-39
40-49
40-49
>3 physicians >4 physicians
Number of Physicians Prior to Diagnosis
160. Young-Onset Patients’ Ethnicity
and Their Diagnosis
1
2
3
4
0
10
20
30
40
50
Number of Physician Prior to Diagnosis
%ofPatientsandSurvivors
Caucasians Hispanic/Latino African Americans
C
aucasiansH
ispanic/Latino
A
frican
A
m
ericans
0
10
20
30
40
Diagnosed in the ER
%ofPatientsandSurvivors
18%
25%
32.0%
P<0.0001
161. Young-Onset Patients were Diagnosed in
Late Stages of the Disease
% of Patients Diagnosed in Each Stage
0.0
0.1
0.2
0.3
0.4
Frequency
Stage at Diagnosis
I II III IV
p<0.03
p<0.001
p<0.0001
Proportion of Patients That Had to See More Than 3 Physicians
162. Most Common Misdiagnoses Reported
by Young-Onset Patients
“I was told I had colitis due to stress”
“I was told I am depressed (by a male doctor)
because I had no children. I was not….”
H
em
orrhoidsIB
S/IB
DA
nem
ia
D
iverticulitis
G
ynecologicalissues
Post-C
hildbirth
sym
ptom
s
A
ppendicitis
O
ther
0
100
200
300
NumberofPatients
164. Caregivers’ Experience
60%
of caregivers did not get all
questions answered at the
patient’s diagnosis and did
understand treatment
risks.
75%
of health care professionals
did NOT provide information
on organizations and support
groups for young-onset
colorectal cancer.
Caregivers N=427
Sex (No.)
Females 376
Males 51
Age (No.)
18-29 45
30-39 289
40-49 92
NA 1
Race / Ethnicity (No.)
White Caucasians 212
Hispanic / Latino 77
African Americans 88
Asians / Pacific Islanders 27
Native Americans 20
Others 3
50%
of doctors did not talk to the
patient's family about their
elevated risk of the disease and
the need for screening 10 years
prior to the patient's age at
diagnosis.
166. Young-Onset Patients Survey Summary
Young adults experience multiple symptoms but they may not be aware of young-onset colorectal
cancer and do not associate their symptoms with CRC. One in four patients delayed reaching out to
their doctor for more than one year.
There is an urgent need to raise awareness among medical professionals of the increasing incidence of
young-onset CRC and that the disease can affect patients under 50 years old.
The majority of young-onset patients and survivors were diagnosed with advanced, metastatic disease,
which is proportionally higher than the overall CRC population.
There is a correlation between late stage diagnosis and the number of different physicians / providers
patients had to visit.
The study was subject to certain limitations, including access to technology, gender bias (~80% female)
and race/ethnicity bias (87% White Caucasian). The Alliance plans to increase its outreach and
enhance diversity among participants in future surveys.
167. Resources are needed to improve the ability for caregivers to manage everyday
tasks, potentially helping caregivers feel more organized and in control.
Tools to care for their loved ones will reduce emotional and physical demands
involved with caregiving that can cause strain and burnout.
The Alliance use these survey results to learn about and track self-reported medical,
psychosocial, and quality of life experiences, allowing our patient and family support
program to develop resources and implement programs for this often overlooked
group.
Young-Onset Caregivers Survey Summary